勃起功能障礙市場規模、佔有率和成長分析（按治療類型、最終用戶和地區）- 產業預測 2025-2032

2023 年全球勃起功能障礙市場規模價值 25 億美元，預計將從 2024 年的 27.2 億美元成長到 2032 年的 53.4 億美元，預測期內（2025-2032 年）的複合年成長率為 8.8%。

勃起功能障礙（ED），即無法達到或維持令人滿意的勃起，是最常見的男性性健康問題，對身心健康有重大影響。這種疾病是由心理因素和生理因素造成的，生理因素包括高血壓、肥胖、糖尿病和吸煙。隨著 ED 盛行率的上升，醫療服務提供者和患者意識的提高，治療方案的市場預計會擴大。然而，由於陰莖植入的高成本仍然是許多尋求有效解決方案的人面臨的重大障礙，市場成長可能會受到阻礙。總體而言，ED 治療市場有望成長，但定價仍然是關鍵挑戰。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

勃起功能障礙市場規模（依治療類型和複合年成長率） (2025-2032)

• 市場概況
• 藥物
• Sildenafil
• 他達拉非
• 伐地那非
• 阿伐那非
• 其他
• 陰莖植入
• 陰莖幫浦
• 其他

勃起功能障礙市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概況
• 醫院和診所
• 門診手術中心
• 藥局
• 其他

勃起功能障礙市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Pfizer（US）
• Eli Lilly and Company（US）
• Bayer AG（Germany）
• Takeda Pharmaceutical Company（Japan）
• Mylan（US）（Now Viatris）
• Viatris（US）
• Teva Pharmaceutical Industries（Israel）
• Sun Pharmaceutical Industries（India）
• Cipla（India）
• Aurobindo Pharma（India）
• Lupin Limited（India）
• Dr. Reddy's Laboratories（India）
• Sandoz（Switzerland）
• Novartis（Switzerland）
• Abbott Laboratories（US）
• Sanofi（France）
• GlaxoSmithKline（GSK）（UK）
• Johnson & Johnson（US）
• Boston Scientific（US）
• Coloplast（Denmark）

結論和建議

Global Erectile Dysfunction Market size was valued at USD 2.5 billion in 2023 and is poised to grow from USD 2.72 billion in 2024 to USD 5.34 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).

Erectile dysfunction (ED), the inability to achieve or maintain a satisfactory erection, is the most common male sexual health issue and significantly impacts both physical and mental well-being. The condition arises from psychological and physiological factors, with the latter including high blood pressure, obesity, diabetes, and smoking. As the prevalence of ED rises, the market for treatment options is expected to expand, driven by increasing awareness among healthcare providers and patients. However, market growth may be hindered by the high costs associated with penile implants, which remain a significant barrier for many looking for effective solutions. Overall, the ED treatment market is poised for growth, but pricing remains a critical challenge.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Erectile Dysfunction market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Erectile Dysfunction Market Segments Analysis

Global Erectile Dysfunction Market is segmented by Treatment Type, End User and region. Based on Treatment Type, the market is segmented into Drugs, Sildenafil, Tadalafil, Vardenafil, Avanafil, Others, Penile Implants, Penis Pumps and Others. Based on End User, the market is segmented into Hospitals & Clinics, Ambulatory Surgery Centers, Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Erectile Dysfunction Market

The Global Erectile Dysfunction market is significantly influenced by the increasing prevalence of diabetes, obesity, and cardiovascular diseases, all of which are linked to unhealthy lifestyle choices. As people age, these conditions contribute to erectile dysfunction (ED), with a particularly concerning trend among younger individuals in emerging countries where stressful lifestyles have led to a rise in fast food consumption, as well as drinking and smoking habits. These factors are undermining overall health and fitness, thereby heightening the risk of developing ED. Moreover, with the senior population on the rise, the number of individuals suffering from ED is expected to increase, further propelling the demand for ED medications globally throughout the forecast period.

Restraints in the Global Erectile Dysfunction Market

The global erectile dysfunction market faces significant restraints, particularly in low- and middle-income countries where sales represent a smaller fraction compared to developed and emerging economies. This limitation stems from several factors, including a general lack of awareness regarding available treatments, restricted purchasing power among potential consumers, and resistance to integrating these medications into daily routines. Additionally, the market's growth is hindered by the adverse side effects associated with erectile dysfunction drugs, such as headaches, nausea, flushing, nasal congestion, visual disturbances, dizziness, diarrhea, and skin rashes, all of which discourage potential users from pursuing treatment options.

Market Trends of the Global Erectile Dysfunction Market

The global erectile dysfunction market is experiencing notable growth, driven primarily by the enduring popularity of sildenafil, commonly known as Viagra. As a cornerstone treatment, sildenafil has demonstrated significant efficacy, with approximately two-thirds of users reporting improved erections, reinforcing its status as the first-line therapy for erectile dysfunction. The market's expansion is further supported by increasing awareness of sexual health, a growing aging population, and the rising incidence of conditions like diabetes and hypertension that contribute to erectile dysfunction. As a result, the erectile dysfunction market is poised for robust growth throughout the projection period, fueled by advancements in treatment options and a rising demand for effective therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Erectile Dysfunction Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Drugs
• Sildenafil
• Tadalafil
• Vardenafil
• Avanafil
• Others
• Penile Implants
• Penis Pumps
• Others

Global Erectile Dysfunction Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgery Centers
• Pharmacies
• Others

Global Erectile Dysfunction Market Size & CAGR (2025-2032)

• North America (Treatment Type, End User)
  • US
  • Canada
• Europe (Treatment Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan (US) (Now Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coloplast (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations